✨ Free AI Report
NeuroPace, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research NeuroPace, Inc.
Company Research

NeuroPace, Inc.: Business Overview, Financials & Competitive Analysis

NeuroPace, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). NeuroPace holds a unique, FDA-approved monopoly in closed-loop brain-responsive epilepsy treatment with accelerating revenue growth and expanding clinical evidence, positioning it for sustained market expansion in a high-value surgical niche.

What is NeuroPace, Inc.'s industry? NeuroPace, Inc. (neuropace.com) operates in Medical Devices - Neuromodulation/Neurostimulation. AskCyborg classifies NeuroPace, Inc. under Medical Devices - Neuromodulation/Neurostimulation in its company registry.

NeuroPace is a medical device company that develops the RNS System, a brain-responsive neuromodulation system delivering personalized, real-time treatment at the seizure source for treating drug-resistant focal epilep...

7/ 10Strong

Cyborg Score thesis

NeuroPace holds a unique, FDA-approved monopoly in closed-loop brain-responsive epilepsy treatment with accelerating revenue...

Read the full analyst-debate transcript →
Industry Medical Devices - Neuromodulation/Neurostimulation
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 12, 2026
AI-Verified Research
30+ Page Report

Get the Latest NeuroPace, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for NeuroPace, Inc.

AskCyborg analysts argue the bull and bear cases for NeuroPace, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
NeuroPace, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

NeuroPace, Inc. Overview

Pro stress-test →

NeuroPace is a medical device company that develops the RNS System, a brain-responsive neuromodulation system delivering personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. The RNS System is the first and only commercially available, brain-responsive neuromodulation device approved by the FDA for this indication.

Strategic Profile

Pro stress-test →

NeuroPace demonstrated 22% revenue growth to $79.9 million in 2024, driven by increased RNS System sales and contributions from a distribution agreement with DIXI Medical. The company operates the only FDA-approved closed-loop neuromodulation system, combining continuous intracranial EEG monitoring and targeted seizure interruption.

Competitive Landscape

Pro stress-test →

NeuroPace operates in a highly specialized market with minimal direct competition in closed-loop brain-responsive epilepsy treatment. Primary competitors include traditional neurosurgical approaches and alternative epilepsy treatments (medications, vagus nerve stimulation), but NeuroPace holds the only FDA-approved invasive responsive neuromodulation system for focal epilepsy. Potential future competitors may emerge in broader neuromodulation markets.

Industry Context

NeuroPace, Inc. operates in Medical Devices - Neuromodulation/Neurostimulation.

Key facts

Founded: 1997 · Headquarters: Mountain View, California · Revenue: $79.9B

What the analysts stress-tested

The top findings that survived the multi-agent debate for NeuroPace, Inc..

  • RNS sales grew 27% year-over-year excluding Nautilus study contribution, indicating strong underlying demand momentum.
  • The NAUTILUS trial for drug-resistant idiopathic generalized epilepsy is on track to complete one-year follow-up in March 2025, potentially expanding addressable patient population.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2025Scott Huennekens appointed to Board of Directors with extensive medtech experience
  • January 2025FY2024 revenue of $79.9M exceeded guidance, representing 22% growth year-over-year
  • +1 moreTrack every material event for NeuroPace, Inc. as it happens. Explore monitoring →
Get alerted when NeuroPace, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Vagus Nerve StimulationNon-responsive neuromodulation for epilepsy→Medical ManagementAnti-seizure medications and drug therapies→

Compare NeuroPace, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

NeuroPace, Inc. operates in Medical Devices - Neuromodulation/Neurostimulation. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Devices - Neuromodulation/Neurostimulation research →
NEW · MCP server

Ask your AI assistant about NeuroPace, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare NeuroPace, Inc. and its top competitor on Cyborg Score”
“What did NeuroPace, Inc. do this quarter?”
“Is NeuroPace, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does NeuroPace, Inc. do?+
NeuroPace is a medical device company that develops the RNS System, a brain-responsive neuromodulation system delivering personalized, real-time treatment at the seizure source for treating drug-resistant focal epilep...
What is NeuroPace, Inc.'s Cyborg Score?+
NeuroPace, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are NeuroPace, Inc.'s main competitors?+
Named competitors include Vagus Nerve Stimulation, Medical Management. The full competitive landscape is in the AskCyborg report.
How can I get the full NeuroPace, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the NeuroPace, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track NeuroPace, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Medical Devices - Neuromodulation research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7CVRx, Inc.6Nyxoah SA